Ken James to lead Futura's R&D

RNS Number : 3022P

Futura Medical PLC

16 November 2016

 

For immediate release                                                                                                16 November 2016

Futura Medical plc

("Futura" or the "Company")

Ken James to lead Futura's R&D

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that Ken James, who was appointed to the Company as a Non-Executive Director in March this year, is joining the Company's executive team as an Executive Director and Head of R&D with immediate effect.

Mr James is the former head of consumer healthcare R&D at GlaxoSmithKline ("GSK"), where he brought more than 200 innovative products to market.

In the newly created role of Head of R&D at Futura, Mr James will oversee the development, regulatory and manufacturing strategies for the Company's existing pipeline of products and the evaluation of earlier stage pipeline opportunities.

Futura intends to recruit a new Non-Executive Director in due course to maintain the depth, balance and independence of its Board.

Mr James's role as Head of R&D will include directing the further development of MED2002, the Company's novel, topical treatment for erectile dysfunction ("ED"), which delivered positive results from a clinical study announced on 7 September 2016 and on which a separate update has today been provided.

James Barder, Futura's Chief Executive, commented: "I am delighted that Ken James has agreed to become an Executive Director in the newly created role of Head of R&D. Since joining Futura's Board in March this year, Ken has made a valuable contribution to the Company's strategic development and I very much look forward to his input as part of the executive team."

Additional Information

The RNS dated 7 March 2016 relating to Mr. James' appointment to Board contained all the necessary regulatory information relating to paragraph (g) of Schedule Two of the AIM Rules for Companies, which remains unchanged.

This announcement contains inside information.

For further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
Email to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Liz Yong	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Cowles / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

BOAGGGQPGUPQUQQ